Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Yulia Tingle"'
Autor:
Mimieveshiofuo Ayala, Dominic P. Williams, Jeffrey Atkinson, Annie Delaunois, Yulia Tingle, Adedamola Olayanju, Ken Meecham, Sabine Pestel, Björn Lemmer, Swaminathan Sethu, Ana Alfirevic, James E. Sidaway, Christopher E. Goldring, Ailsa Dermody, Awel W. Williams, Junnat M. Hamdam, Trevor R.F. Smith, Kevin Park, Emma Smith, Mohammad Alhaidari, Rowena Sison-Young, Karthik Govindappa, Gerry Kenna, Jean-Pierre Valentin, Helen Box, Michael J. Cross, Rosalind E. Jenkins, Andreas Rothfuss, Jean-Michel Guillon, Richard Stebbings
Publikováno v:
Toxicology and Applied Pharmacology. 273:229-241
Safety pharmacology (SP) is an essential part of the drug development process that aims to identify and predict adverse effects prior to clinical trials. SP studies are described in the International Conference on Harmonisation (ICH) S7A and S7B guid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45178ceb5a609742f9897151e0020ac2
https://doi.org/10.1016/j.taap.2013.04.039
https://doi.org/10.1016/j.taap.2013.04.039
Autor:
Yulia Tingle, Neil R. Kitteringham, Jean G. Sathish, Laiche Djouhri, Laith M. A. Al-Huseini, Junnat M. Hamdam, B. Kevin Park, Swaminathan Sethu, Han Xian Aw Yeang, Naif Alhumeed, Christopher E. Goldring
Publikováno v:
The Journal of Biological Chemistry
Background: Nrf2 is required for normal dendritic cell immune functions. Results: Loss of Nrf2 alters DC function and results in hyperphosphorylation of CREB/ATF1 transcription factors that are responsive to p38 MAPK inhibition. Conclusion: The p38 M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb5d61f305021ec3b21921241cdb4f08
http://europepmc.org/articles/PMC3829319
http://europepmc.org/articles/PMC3829319